You are here

Generic Equivalent of Ultracet Granted Final Approval by FDA

DETROIT, Dec. 19 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd., (AMEX:CPD) announced today that the US Food and Drug Administration (FDA) have granted final approval for the Company's Abbreviated New Drug Application (ANDA) for Tramadol Hydrochloride with Acetaminophen Tablets.

Caraco's Tramadol Hydrochloride (HCl) with Acetaminophen Tablets is the generic equivalent of Ortho-McNeil Pharmaceutical Inc. brand product, Ultracet(R), which is indicated for the short-term (five days or less) management of acute pain.

"We are extremely pleased on receiving this approval and plan to launch this product to the market immediately," said Daniel H. Movens, Chief Executive Officer. "This approval brings our total product portfolio to 19 different products represented by 41 strengths."

Source: Caraco Pharmaceutical Laboratories

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs